FOR IMMEDIATE RELEASE: February 29, 2016
DENVER NORML FILES MARIJUANA SOCIAL USE INITIATIVE for 2016 CITY BALLOT
Would Legalize Private Marijuana Social Clubs and Special Events Where Marijuana Could be Consumed
Denver, CO – The Denver Chapter of the National Organization for the Reform of Marijuana Laws (Denver NORML) submitted an initiative today that would legalize marijuana clubs and special events in the city in 2016.
“Denver residents and visitors alike need places other than private homes to legally and responsibly enjoy legal marijuana with other adults,” said Jordan Person, executive director of Denver NORML.
“This submission to city council is the first step. We’ll get feedback from the city, finalize the language, then start gathering signatures to put it on the ballot,” Person said. If Denver voters approve this November, private 21+ marijuana social clubs will become legal, as will private 21+ events where marijuana can be lawfully consumed.
“The city will be able to license and regulate private marijuana clubs and special events to ensure public health and safety,” Person said. “But we want to be sure that the regulations are reasonable and consumer-friendly.”
Clubs would be stand-alone venues which could not sell or distribute marijuana, and bars, nightclubs and restaurants could not become private marijuana clubs, Jordan said. “We expect there will be a wide range of clubs to serve Denver’s huge and diverse marijuana market,” Jordan said. “What can’t continue is the current situation that leaves so many people frustrated, angry, and tempted to violate the law so they can enjoy a legal product.”
Since its founding in1970, NORML has been the leading voice for marijuana consumers, and for the end of prohibition that treats otherwise law-abiding marijuana smokers like criminals.
Poll: 60 Percent of Likely California Voters Support Initiative Effort To Legalize Adult Marijuana UseFebruary 25, 2016
A majority of likely California voters say that they intend to vote ‘yes’ this November for an initiative to regulate the retail production and sale of marijuana by adults, according to the results of a Probolsky Research poll released today.
Sixty percent of respondents say that they will vote in favor of an initiative this November “that would legalize marijuana for recreational use under California law and allow government to tax” its retail sales. Thirty-seven percent said that they would vote ‘no.’
Support was strongest among those between the ages of 18 to 34 (80 percent) and self-identified Democrats (69 percent). Republicans (38 percent) and those over the age of 65 (46 percent) were least likely to express support.
The Adult Use of Marijuana Act (AUMA), which is expected to appear on the November ballot, permits adults to legally grow (up to six plants) and possess personal use quantities of cannabis (up to one ounce of flower and/or up to eight grams of concentrate) while also licensing commercial cannabis production and retail sales. The measure prohibits localities from taking actions to infringe upon adults’ ability to possession and cultivate cannabis for non-commercial purposes. Both the California Medical Association and the state chapter of the NAACP have endorsed the measure.
On February 20, a majority of the NORML Board of Directors endorsed the AUMA, along with separate initiatives that are anticipated to appear on the November 2016 ballot in Maine, Massachusetts, Nevada, and Arizona, as well as medical use initiatives expected to appear on the ballot in Missouri and Florida.
Members of Australia’s House and Senate approved legislation this week to amend federal law to permit for the licensed production and distribution of cannabis to qualified patients.
The measure amends the Narcotic Drugs Act of 1967 to allow “for the cultivation and production of cannabis and cannabis resin for medicinal and scientific purposes,” and to authorize “a state or territory government agency to undertake [in the] cultivation and production of cannabis and [in the] manufacture of medicinal cannabis products.”
The move by Parliament follows recent efforts by several Australian territories to provide patients participating in clinical trials with access to the plant.
“This is an historic day for Australia and the many advocates who have fought long and hard to challenge the stigma around medicinal cannabis products so genuine patients are no longer treated as criminals,” Minister for Health Sussan Ley said in a statement. “This is the missing piece in a patient’s treatment journey and will now see seamless access to locally-produced medicinal cannabis products from farm to pharmacy.”
Government officials will still need to develop and approve regulations for the new program before any production licenses can be issued.
Canada, Israel, and the Netherlands are among the handful of nations that presently provide federal licenses to private growers to supply medical marijuana to qualified patients. Colombia, Jamaica, and Puerto Rico are also expected to begin licensing medical marijuana manufacturing in the near future.
In 2013, Uruguay officials approved legislation authorizing the retail production and sale of cannabis to those age 18 and older. Consumers in that country are anticipated to be able to begin purchasing cannabis at state-licensed pharmacies by mid-2016.
A federal court in Canada ruled today that government officials cannot prohibit physician-authorized patients from growing their own supply of medical cannabis.
The decision strikes down regulations enacted in 2013 that sought to take away patients’ longstanding authority to grow personal use quantities of cannabis. The court opined that the regulations unduly infringed upon patients’ liberties and that they were “not in accordance with the principles of fundamental justice.”
The judge’s ruling provides Parliament with six months to create new rules governing the regulation and distribution of medical cannabis in a manner that no longer requires patients to obtain medicine solely from federally-licensed, private third party providers.
NORML Canada‘s John Conroy served as lead counsel for the plaintiffs in the case, while NORML Deputy Director Paul Armentano served as an expert witness and filed an affidavit in the case.
Canadian officials first legalized the physician authorized use, possession, and home cultivation of medical marijuana in 2001. Those regulations were significantly amended in 2013 in a manner that sought to prohibit qualified patients from continuing to receive cannabis from Health Canada or from growing it themselves.
Last year, newly elected Prime Minister Justin Trudeau promised to amend Canada’s marijuana laws in a manner that regulates the plant’s use and sale for all adults.
Text of the decision, Allard et al. v Canada, is online here.
The long-term, daily use of cannabis is associated with improved analgesia and reduced opioid use in patients with treatment-resistant chronic pain conditions, according to clinical trial data reported online ahead of print in The Clinical Journal of Pain.
Investigators with Hebrew University in Israel evaluated the use of cannabis on pain in a cohort of 176 patients, each of whom had been previously unresponsive to all conventional pain medications. Subjects inhaled THC-dominant cannabis daily (up to 20 grams per month) for a period of at least six months.
A majority of participants (66 percent) experienced improvement in their pain symptom scores after cannabis therapy, and most reported “robust” improvements in their quality of life. Subjects’ overall consumption of opioid drugs declined 44 percent by the end of the trial, and a significant percentage of participants discontinued opioid therapy altogether over the course of the study.
Authors concluded, “In summary, this long-term prospective cohort suggests that cannabis treatment in a mixed group of patients with treatment-resistant chronic pain may result in improved pain, sleep and quality of life outcomes, as well as reduced opioid use.”
The Israeli results are similar to those reported in a 2015 Canadian trial which concluded that chronic pain patients who use herbal cannabis daily for one-year experienced reduced discomfort and increased quality of life compared to controls, and did not possess an increased risk of serious side effects.
According to data published in 2014 in The Journal of the American Medical Association, US states with medical marijuana laws experience far fewer opiate-related deaths than do states that prohibit the plant. Investigators from the RAND Corporation and the University of California, Irvine reported similar findings in 2015, concluding, “States permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not.” Clinical data published in 2011 in the journal Clinical Pharmacology & Therapeutics previously reported that the administration of vaporized cannabis “safely augments the analgesic effect of opioids.”
A review published earlier this year in the Canadian Journal of Anesthesia assessing the clinical use of cannabinoids for pain in over 1,300 subjects concludes, “Overall, the recent literature supports the idea that currently available cannabinoids are modestly effective analgesics that provide a safe, reasonable therapeutic option for managing chronic non-cancer-related pain and possibly cancer-related pain.”
An abstract of the study, “The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: A prospective open-label study,” appears online here.